E-ISSN 2231-3206 | ISSN 2320-4672
 
2024, Vol: 14, Issue: 4
14 / 4Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Authorship Declaration

Original Research

Online Publishing Date:
21 / 05 / 2022

 


Prevalence, severity, and trends in drug therapy of COVID-19 breakthrough infection at L-3 COVID Hospital, Bareilly: A cross-sectional study

Anju Saxena, Iram Shaifali, Shalini Chandra, Manohar Yazali.


Abstract
Background: The COVID-19 pandemic has led to dramatic loss of human life worldwide and presents an unprecedented challenge to public health, food systems, and the world of work. The availability of a safe and effective vaccine for COVID-19 is well recognized as an additional tool to contribute to the control of the pandemic. Although vaccines proved efficacious in preventing infection, yet some cases of post-vaccination breakthrough infections (BTIs) have been reported, raising concerns about the efficacy and safety of COVID vaccines.

Aim and Objectives: This study was aimed to investigate the occurrence of BTIs among the vaccinated healthcare workers (HCWs), to analyze the severity of their disease and to know the trends in drug therapy.

Materials and Methods: This was a retrospective cross-sectional study. Data were obtained by a predesigned questionnaire and was distributed through Google platform. Details of time, severity of BTIs and the trends in drug therapy among the vaccinated healthcare workers (HCWs) was evaluated and statistically analyzed.

Results: A total of 616 HCWs participated in the study, out of which 553 were vaccinated and 63 of them were unvaccinated. About 15%, that is, 85/553 of the vaccinated HCWs developed BTI. Case rate was lesser (12.9%) in fully vaccinated HCWs as compared to partially vaccinated HCWs (19.5%). Most BTI cases (94%) suffered mild to moderate severity of symptoms and were managed in home isolation with medicines (mainly paracetamol, azithromycin, and doxycycline). Only five out of 85 BTI cases developed severe disease and needed hospitalization.

Conclusion: BTIs after COVID-19 vaccination are uncommon and typically present with mild symptoms. Thus, vaccination along with hand sanitization, wearing of masks, and maintaining social distancing has provided hope in combating the pandemic.

Key words: COVID-19; Post Vaccination; Breakthrough Infection; Drug Therapy


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Anju Saxena
Articles by Iram Shaifali
Articles by Shalini Chandra
Articles by Manohar Yazali
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Saxena A, Shaifali I, Chandra S, Yazali M. Prevalence, severity, and trends in drug therapy of COVID-19 breakthrough infection at L-3 COVID Hospital, Bareilly: A cross-sectional study. Natl J Physiol Pharm Pharmacol. 2022; 12(12): 2110-2114. doi:10.5455/njppp.2022.12.04190202209052022

Web Style

Saxena A, Shaifali I, Chandra S, Yazali M. Prevalence, severity, and trends in drug therapy of COVID-19 breakthrough infection at L-3 COVID Hospital, Bareilly: A cross-sectional study. https://www.njppp.com/?mno=26571 [Access: March 14, 2024]. doi:10.5455/njppp.2022.12.04190202209052022

AMA (American Medical Association) Style

Saxena A, Shaifali I, Chandra S, Yazali M. Prevalence, severity, and trends in drug therapy of COVID-19 breakthrough infection at L-3 COVID Hospital, Bareilly: A cross-sectional study. Natl J Physiol Pharm Pharmacol. 2022; 12(12): 2110-2114. doi:10.5455/njppp.2022.12.04190202209052022


Vancouver/ICMJE Style

Saxena A, Shaifali I, Chandra S, Yazali M. Prevalence, severity, and trends in drug therapy of COVID-19 breakthrough infection at L-3 COVID Hospital, Bareilly: A cross-sectional study. Natl J Physiol Pharm Pharmacol. (2022), [cited March 14, 2024]; 12(12): 2110-2114. doi:10.5455/njppp.2022.12.04190202209052022


Harvard Style

Saxena, A., Shaifali, . I., Chandra, . S. & Yazali, . M. (2022) Prevalence, severity, and trends in drug therapy of COVID-19 breakthrough infection at L-3 COVID Hospital, Bareilly: A cross-sectional study. Natl J Physiol Pharm Pharmacol, 12 (12), 2110-2114. doi:10.5455/njppp.2022.12.04190202209052022


Turabian Style

Saxena, Anju, Iram Shaifali, Shalini Chandra, and Manohar Yazali. 2022. Prevalence, severity, and trends in drug therapy of COVID-19 breakthrough infection at L-3 COVID Hospital, Bareilly: A cross-sectional study. National Journal of Physiology, Pharmacy and Pharmacology, 12 (12), 2110-2114. doi:10.5455/njppp.2022.12.04190202209052022


Chicago Style

Saxena, Anju, Iram Shaifali, Shalini Chandra, and Manohar Yazali. "Prevalence, severity, and trends in drug therapy of COVID-19 breakthrough infection at L-3 COVID Hospital, Bareilly: A cross-sectional study." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 2110-2114. doi:10.5455/njppp.2022.12.04190202209052022


MLA (The Modern Language Association) Style

Saxena, Anju, Iram Shaifali, Shalini Chandra, and Manohar Yazali. "Prevalence, severity, and trends in drug therapy of COVID-19 breakthrough infection at L-3 COVID Hospital, Bareilly: A cross-sectional study." National Journal of Physiology, Pharmacy and Pharmacology 12.12 (2022), 2110-2114. Print. doi:10.5455/njppp.2022.12.04190202209052022


APA (American Psychological Association) Style

Saxena, A., Shaifali, . I., Chandra, . S. & Yazali, . M. (2022) Prevalence, severity, and trends in drug therapy of COVID-19 breakthrough infection at L-3 COVID Hospital, Bareilly: A cross-sectional study. National Journal of Physiology, Pharmacy and Pharmacology, 12 (12), 2110-2114. doi:10.5455/njppp.2022.12.04190202209052022


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

  National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal.  The journal is having open access polic ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Publisher

publishernjppp@gmail.com

 

Editorial query

editornjppp1@gmail.com

MOB - 8780040272